Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece

被引：0

作者：

Tzanetakos, C. ^{[1
]}

Kourlaba, G. ^{[2
]}

Hatzikou, M. ^{[3
]}

Antoniou, C. ^{[4
]}

Ioannides, D. ^{[5
]}

Lefaki, I. ^{[6
]}

Petridis, A. ^{[7
]}

Rigopoulos, D. ^{[8
]}

Roussaki-Schulze, V. ^{[9
]}

Sotiriadis, D. ^{[10
]}

Maniadakis, N. ^{[1
]}

机构：

[1] Natl Sch Publ Hlth, Hlth Serv Org & Management, Athens, Greece

[2] Aghia Sophia Childrens Hosp, Collaborat Ctr Clin Epidemiol & Outcomes Res CLEO, Athens, Greece

[3] Novartis Hellas SACI SA, Athens, Greece

[4] Univ Athens, Hosp Venereol Dermatol Dis A Syggros, Athens, Greece

[5] Aristoteleio Univ Thessaloniki, Hosp Skin & Venereal Dis, Thessaloniki, Greece

[6] Hosp Skin & Venereal Dis, Dermatol Clin, Thessaloniki, Greece

[7] Hosp Venereol Dermatol Dis A Syggros, Dermatol Clin, Athens, Greece

[8] Univ Athens, Attikon Univ Hosp Athens, Athens, Greece

[9] Univ Thessaly, Univ Hosp Larissa, Larisa, Greece

[10] Aristoteleio Univ Thessaloniki, Gen Hosp Thessaloniki PAPAGEORGIOU, Thessaloniki, Greece

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷

关键词：

cost-effectiveness; plaque psoriasis; secukinumab;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P125

引用

页码：61 / 62

页数：2

共 50 条

[1] COST-EFFECTIVENESS OF SECUKINUMAB COMPARED WITH USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
Tzanetakos, C.
Kourlaba, G.
Chatzikou, M.
Antoniou, C.
Ioannidis, D.
Lefaki, I
Petridis, A.
Rigopoulos, D.
Roussaki-Schulze, A.
Sotiriadis, D.
Maniadakis, N.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A569 - A569
[2] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE CZECH REPUBLIC
Klimes, J.
Mollon, P.
Graham, C.
Rajnoch, J.
Dostal, F.
Skalicky, D.
Jordan, P.
Depta, J.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A424 - A424
[3] COST-EFFECTIVENESS OF USTEKINUMAB IN THE MANAGEMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN MEXICO
Valencia-Mendoza, A.
Hernandez-Garduno, A.
Puig, A.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A513 - A514
[4] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
Rouse, Nicole C.
Farhangian, Michael E.
Wehausen, Brooke
Feldman, Steven R.
[J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
[5] COST EFFECTIVENESS OF TREATMENT WITH ETANERCEPT OR USTEKINUMAB FOR MODERATE TO SEVERE PSORIASIS
Villacorta, R.
Hay, J.
Messali, A.
[J]. VALUE IN HEALTH, 2012, 15 (04) : A103 - A103
[6] COST-EFFECTIVENESS ANALYSIS OF BIMEKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
Koulentaki, M.
Tzanetakos, C.
Stratigos, A.
Sotiriou, E.
Ladha, I
Christou, P.
Relakis, J.
Kourlaba, G.
[J]. VALUE IN HEALTH, 2022, 25 (12) : S74 - S74
[7] ASSESSMENT OF THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS RISANKIZUMAB FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN THE UK
Moreno, S.
Walsh, S.
Khanna, P. J.
Jain, M.
Tanova-Yotova, N.
[J]. VALUE IN HEALTH, 2022, 25 (12) : S89 - S89
[8] COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
Solakidi, A.
Tzanetakos, C.
Kontodimas, S.
Kourlaba, G.
[J]. VALUE IN HEALTH, 2018, 21 : S428 - S428
[9] Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis
Ferrandiz, C.
Garcia, A.
Blasco, A. J.
Lazaro, P.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (06) : 768 - 777
[10] Cost-effectiveness of treatment for moderate-to-severe psoriasis
Hankin, CS
Feldman, SR
Pearce, D
[J]. VALUE IN HEALTH, 2004, 7 (06) : 654 - 654

← 1 2 3 4 5 →